WILMINGTON, Del., June 02, 2024--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC
The UK stock market's up by double digits this year, but will this momentum continue? And is 2024 a last chance to capitalise on once-in-a-decade bargains? The post 2024 stock market rally: a final chance for once-in-a-decade bargains? appeared first on The Motley Fool UK.
In this article, we will be taking a look at the most profitable biotechnology company in the world. If you want to learn about more, head straight to the 15 Most Profitable Biotechnology Companies in the World. Global Biotechnology Market Forecast: Strong Growth Driven by Healthcare and Food & Agriculture Innovations The global biotechnology market was valued […]